Browsing by title
Now showing items 1468-1487 of 4595
-
EGFR Exon 20 Insertion Mutations in Sinonasal Squamous Cell Carcinoma.
(MDPI, 2022-01-13)Recurrent epidermal growth factor receptor (EGFR)-activating mutations have been identified in a rare form of head and neck cancer known as sinonasal squamous cell carcinoma (SNSCC), a malignant disease with a 5-year ... -
EGFR feedback-inhibition by Ran-binding protein 6 is disrupted in cancer.
(NATURE PUBLISHING GROUP, 2017-12-11)Transport of macromolecules through the nuclear pore by importins and exportins plays a critical role in the spatial regulation of protein activity. How cancer cells co-opt this process to promote tumorigenesis remains ... -
EGFR signaling in invasion, angiogenesis and metastasis
(Humana Press, 2008-09-25)Tumour invasion and metastasis are the hallmarks of advanced stage cancer and are associated with poor patient prognosis. EGFR is overexpressed in a variety of tumour types and this frequently correlates with a more ... -
Eighty per cent more patients in 10 years of UK molecular radiotherapy: Internal Dosimetry Users Group survey results from 2007 to 2017.
(LIPPINCOTT WILLIAMS & WILKINS, 2019-07-01) -
Elacestrant demonstrates strong anti-estrogenic activity in PDX models of estrogen-receptor positive endocrine-resistant and fulvestrant-resistant breast cancer.
(NATURE PORTFOLIO, 2022-11-29)The selective oestrogen receptor (ER) degrader (SERD), fulvestrant, is limited in its use for the treatment of breast cancer (BC) by its poor oral bioavailability. Comparison of the orally bioavailable investigational SERD ... -
Elderly patients with gastrointestinal stromal tumour (GIST) receive less treatment irrespective of performance score or comorbidity - A retrospective multicentre study in a large cohort of GIST patients.
(2017-11)Objective Although gastrointestinal stromal tumours (GIST) predominantly occur in older patients, data on treatment patterns in elderly GIST patients are scarce.Methods Patients registered in the Dutch GIST Registry (DGR) ... -
Elevated APOBEC3B expression drives a kataegic-like mutation signature and replication stress-related therapeutic vulnerabilities in p53-defective cells.
(NATURE PUBLISHING GROUP, 2017-06-27)BACKGROUND: Elevated APOBEC3B expression in tumours correlates with a kataegic pattern of localised hypermutation. We assessed the cellular phenotypes associated with high-level APOBEC3B expression and the influence of p53 ... -
Elevated Platelet Count Appears to Be Causally Associated with Increased Risk of Lung Cancer: A Mendelian Randomization Analysis.
(AMER ASSOC CANCER RESEARCH, 2019-05-01)BACKGROUND: Platelets are a critical element in coagulation and inflammation, and activated platelets are linked to cancer risk through diverse mechanisms. However, a causal relationship between platelets and risk of lung ... -
ELM-the eukaryotic linear motif resource in 2020.
(OXFORD UNIV PRESS, 2020-01-08)The eukaryotic linear motif (ELM) resource is a repository of manually curated experimentally validated short linear motifs (SLiMs). Since the initial release almost 20 years ago, ELM has become an indispensable resource ... -
ELM-the Eukaryotic Linear Motif resource-2024 update.
(OXFORD UNIV PRESS, 2024-01-05)Short Linear Motifs (SLiMs) are the smallest structural and functional components of modular eukaryotic proteins. They are also the most abundant, especially when considering post-translational modifications. As well as ... -
ELM: the status of the 2010 eukaryotic linear motif resource.
(OXFORD UNIV PRESS, 2010-01-01)Linear motifs are short segments of multidomain proteins that provide regulatory functions independently of protein tertiary structure. Much of intracellular signalling passes through protein modifications at linear motifs. ... -
Elongin C (ELOC/TCEB1)-associated von Hippel-Lindau disease.
(OXFORD UNIV PRESS, 2022-08-23)Around 95% of patients with clinical features that meet the diagnostic criteria for von Hippel-Lindau disease (VHL) have a detectable inactivating germline variant in VHL. The VHL protein (pVHL) functions as part of the ... -
Elucidating Prostate Cancer Behaviour During Treatment via Low-pass Whole-genome Sequencing of Circulating Tumour DNA.
(ELSEVIER, 2021-08-01)BACKGROUND: Better blood tests to elucidate the behaviour of metastatic castration-resistant prostate cancer (mCRPC) are urgently needed to drive therapeutic decisions. Plasma cell-free DNA (cfDNA) comprises normal and ... -
Elucidating Prostate Cancer Immunopathology and Immunogenomics Utilizing Computational Analyses of Digital Imaging
(Institute of Cancer Research (University Of London), 2024-01-05)Prostate Cancer (PCa) is a prominent non-cutaneous malignancy in men in developed countries, necessitating effective treatments. Chronic inflammation is a key factor in PCa pathogenesis and progression, involving a ... -
Embracing the complexity: Older adults with cancer-related cognitive decline-A Young International Society of Geriatric Oncology position paper.
(ELSEVIER, 2020-03-01)Cancer-related cognitive decline (CRCD) may have particularly significant consequences for older adults, impacting their functional and physical abilities, level of independence, ability to make decisions, treatment ... -
Embryonal Rhabdomyosarcoma of the Ovary and Fallopian Tube: Rare Neoplasms Associated With Germline and Somatic DICER1 Mutations.
(LIPPINCOTT WILLIAMS & WILKINS, 2020-06-01)DICER1 mutations (somatic or germline) are associated with a variety of uncommon neoplasms including cervical and genitourinary embryonal rhabdomyosarcoma (ERMS). We report a primary ovarian and 2 primary fallopian tube ... -
Embryonic transcription factor SOX9 drives breast cancer endocrine resistance.
(2017-05-15)The estrogen receptor (ER) drives the growth of most luminal breast cancers and is the primary target of endocrine therapy. Although ER blockade with drugs such as tamoxifen is very effective, a major clinical limitation ... -
Emergence of Enzalutamide Resistance in Prostate Cancer is Associated with BCL-2 and IKKB Dependencies.
(AMER ASSOC CANCER RESEARCH, 2021-04-15)PURPOSE: Although enzalutamide (ENZ) has been widely used to treat de novo or castration-resistant metastatic prostate cancer, resistance develops and disease progression is ultimately inevitable. There are currently no ... -
Emerging biomarkers for PD-1 pathway cancer therapy.
(2017-01)The field of immuno-oncology has witnessed unprecedented success in recent years, with several PD=1 and PD-L1 inhibitors obtaining US FDA registration and breakthrough drug therapy designation in multiple tumor types. ... -
The Emerging Role of PET/CT with PSMA-Targeting Radiopharmaceuticals in Clear Cell Renal Cancer: An Updated Systematic Review.
(MDPI, 2023-01-05)BACKGROUND: Recent articles proposed the employment of positron emission tomography/computed tomography (PET/CT) with prostate-specific membrane antigen (PSMA)-targeting radiopharmaceuticals in clear cell renal cell carcinoma ...